Activated Partial Thromboplastin Time and Risk of Future Venous Thromboembolism

Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thro...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of medicine Vol. 121; no. 3; pp. 231 - 238
Main Authors Zakai, Neil A., Ohira, Tetsuya, White, Richard, Folsom, Aaron R., Cushman, Mary
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.03.2008
Elsevier
Elsevier Sequoia S.A
Subjects
Online AccessGet full text
ISSN0002-9343
1555-7162
1555-7162
DOI10.1016/j.amjmed.2007.10.025

Cover

Loading…
Abstract Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor ( P interaction <.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
AbstractList Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor ( P interaction <.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency.BACKGROUNDLower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency.In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors.METHODSIn the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors.After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction<.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer.RESULTSAfter adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction<.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer.A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.CONCLUSIONA single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction<.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction < .01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
Abstract Background Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. Methods In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. Results After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor ( P interaction <.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. Conclusion A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
Author Ohira, Tetsuya
White, Richard
Folsom, Aaron R.
Zakai, Neil A.
Cushman, Mary
AuthorAffiliation 5 Department of Medicine, University of Vermont, Burlington
2 Division of Epidemiology and Community Health, University of Minnesota, Minneapolis
1 Department of Medicine, Brown University Providence, RI
3 Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka Medical Center, Osaka, Japan
4 Department of Medicine, University of California Davis Medical Center, Sacramento
AuthorAffiliation_xml – name: 1 Department of Medicine, Brown University Providence, RI
– name: 5 Department of Medicine, University of Vermont, Burlington
– name: 3 Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka Medical Center, Osaka, Japan
– name: 2 Division of Epidemiology and Community Health, University of Minnesota, Minneapolis
– name: 4 Department of Medicine, University of California Davis Medical Center, Sacramento
Author_xml – sequence: 1
  givenname: Neil A.
  surname: Zakai
  fullname: Zakai, Neil A.
  organization: Department of Medicine, Brown University and Boston University, Providence, RI
– sequence: 2
  givenname: Tetsuya
  surname: Ohira
  fullname: Ohira, Tetsuya
  organization: Division of Epidemiology and Community Health, University of Minnesota, Minn
– sequence: 3
  givenname: Richard
  surname: White
  fullname: White, Richard
  organization: Department of Medicine, University of California Davis Medical Center, Sacramento
– sequence: 4
  givenname: Aaron R.
  surname: Folsom
  fullname: Folsom, Aaron R.
  organization: Division of Epidemiology and Community Health, University of Minnesota, Minn
– sequence: 5
  givenname: Mary
  surname: Cushman
  fullname: Cushman, Mary
  email: mary.cushman@uvm.edu
  organization: Department of Medicine, University of Vermont, Burlington
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20180776$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18328308$$D View this record in MEDLINE/PubMed
BookMark eNqVkm9rFDEQxoNU7LX6DUQWQd_dOcn-SVaKUEqrQqGip29DNjtrc91NziR70G_fLHc9tSBFQgiZ_OZJZp4ckQPrLBLyksKCAq3erRZqWA3YLhgAT6EFsPIJmdGyLOecVuyAzACAzeu8yA_JUQirtIW6rJ6RQypyJnIQM3J1qqPZqIht9kX5aFSfLa-9Gxq37lWIxmZLM2CmbJt9NeEmc112McbRY_YDrRvDPY1p9iYMz8nTTvUBX-zWY_L94nx59ml-efXx89np5VxXNYtzpWtFBS24EE1NS1Q16Apz2rSsEFx0pWgQQGjVMlGUFQjkqu0Q6k43BStUfkw-bHXXY5OaoNFGr3q59mZQ_lY6ZeTfJ9Zcy59uIxmrSwZlEni7E_Du14ghysEEjX2vLKa6JIecF7xiCXz9AFy50dtUnGR5GskLmqBXfz5n_477RifgzQ5QQau-88pqE_ZcUhHAeZW4Ystp70Lw2P2WAjn5Lldy67ucfJ-iyfeU9v5BmjZRReOm4k3_WPKul5gM2xj0MmiDVmNrPOooW2f-V0D3xppU5w3eYtj3i8rAJMhv07-cviVwoFBXkARO_i3w-P13PpL0OQ
CODEN AJMEAZ
CitedBy_id crossref_primary_10_1039_C8FO02324G
crossref_primary_10_1016_j_jff_2016_02_026
crossref_primary_10_3390_diagnostics13010150
crossref_primary_10_1016_j_wneu_2022_08_099
crossref_primary_10_1093_hmg_ddw401
crossref_primary_10_1177_15330338231186790
crossref_primary_10_1016_j_jns_2012_03_011
crossref_primary_10_1016_j_ajhg_2012_05_009
crossref_primary_10_1002_ajh_24005
crossref_primary_10_1002_rth2_12200
crossref_primary_10_1016_j_tvjl_2016_03_027
crossref_primary_10_1161_CIRCULATIONAHA_115_016537
crossref_primary_10_7759_cureus_51483
crossref_primary_10_1016_j_numecd_2020_03_015
crossref_primary_10_1111_jth_12665
crossref_primary_10_1002_cam4_7231
crossref_primary_10_1016_j_amjms_2017_03_031
crossref_primary_10_1155_2016_5675084
crossref_primary_10_1093_ndt_gfq179
crossref_primary_10_1111_jth_12787
crossref_primary_10_1089_jmf_2014_3307
crossref_primary_10_1111_jth_15870
crossref_primary_10_1016_j_jff_2023_105785
crossref_primary_10_1016_j_thromres_2013_05_014
crossref_primary_10_3390_cancers15010315
crossref_primary_10_1002_rth2_12815
crossref_primary_10_1016_j_jescts_2017_08_001
crossref_primary_10_7759_cureus_27164
crossref_primary_10_1111_j_1538_7836_2011_04443_x
crossref_primary_10_1016_j_jstrokecerebrovasdis_2015_06_008
crossref_primary_10_1038_s41598_019_46644_4
crossref_primary_10_1093_hmg_ddu732
crossref_primary_10_1111_bjh_18288
crossref_primary_10_1111_jth_13446
crossref_primary_10_1016_j_annepidem_2014_08_004
crossref_primary_10_1111_jth_14676
crossref_primary_10_1016_j_thromres_2017_06_021
crossref_primary_10_2147_PGPM_S321084
crossref_primary_10_1007_s10068_022_01241_6
crossref_primary_10_1530_EJE_08_0725
crossref_primary_10_3389_fcvm_2024_1308017
crossref_primary_10_1016_j_amjmed_2019_03_021
crossref_primary_10_1007_s11739_023_03383_9
crossref_primary_10_1016_S0749_4041_09_79137_7
crossref_primary_10_1212_WNL_0000000000207771
crossref_primary_10_1248_yakushi_132_683
Cites_doi 10.1056/NEJM199402243300801
10.1055/s-0037-1613379
10.1111/j.1538-7836.2004.01033.x
10.1016/1047-2797(91)90005-W
10.1016/1047-2797(92)90017-K
10.1055/s-0038-1649589
10.1093/oxfordjournals.aje.a115184
10.1046/j.1365-2257.2001.00421.x
10.1055/s-0037-1613999
10.1016/j.amjmed.2004.01.018
10.1046/j.1538-7836.2003.00459.x
10.1182/blood-2004-03-1042
10.1055/s-0037-1613227
10.1182/blood-2002-05-1416
10.1161/01.CIR.96.4.1102
10.1016/0021-9681(85)90109-2
10.1111/j.1538-7836.2006.01868.x
10.1016/S0002-9343(02)01345-1
10.1016/0895-4356(91)90155-3
10.1016/j.amjmed.2005.03.012
ContentType Journal Article
Copyright 2008 Elsevier Inc.
Elsevier Inc.
2008 INIST-CNRS
Copyright Elsevier Sequoia S.A. Mar 2008
Copyright_xml – notice: 2008 Elsevier Inc.
– notice: Elsevier Inc.
– notice: 2008 INIST-CNRS
– notice: Copyright Elsevier Sequoia S.A. Mar 2008
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7TO
7TS
7U9
H94
K9.
7X8
5PM
DOI 10.1016/j.amjmed.2007.10.025
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Physical Education Index
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Neurosciences Abstracts
Physical Education Index
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1555-7162
EndPage 238
ExternalDocumentID PMC2295205
1455541081
18328308
20180776
10_1016_j_amjmed_2007_10_025
S0002934307010960
1_s2_0_S0002934307010960
Genre Journal Article
Research Support, N.I.H., Extramural
Feature
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: N01-HC-55016
– fundername: NHLBI NIH HHS
  grantid: N01 HC055016
– fundername: NHLBI NIH HHS
  grantid: R01-HL-59367
– fundername: NHLBI NIH HHS
  grantid: R01 HL059367
– fundername: NHLBI NIH HHS
  grantid: N01 HC055019
– fundername: NHLBI NIH HHS
  grantid: N01 HC055022
– fundername: NHLBI NIH HHS
  grantid: N01-HC-55022
– fundername: NHLBI NIH HHS
  grantid: N01-HC-55018
– fundername: NHLBI NIH HHS
  grantid: N01 HC055018
– fundername: NHLBI NIH HHS
  grantid: N01 HC055021
GroupedDBID ---
--K
-~X
.-4
.1-
.55
.FO
.GJ
0R~
123
1B1
1CY
1P~
1RT
1~5
23M
3O-
4.4
457
4CK
4G.
53G
5RE
5VS
6J9
7-5
AAEDT
AAEDW
AAFWJ
AALRI
AAQFI
AAQQT
AAQXK
AAWTL
AAXUO
AAYWO
ABLJU
ABMAC
ABOCM
ABPPZ
ABWVN
ACGFO
ACIUM
ACKOT
ACPRK
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
ADVLN
AENEX
AEUPX
AEVXI
AFFNX
AFHKK
AFJKZ
AFPUW
AFRHN
AFTJW
AGCQF
AGHFR
AGQPQ
AHHHB
AHMBA
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BELOY
BKOMP
C5W
CS3
EBS
EFJIC
EFKBS
EJD
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
G-2
G-Q
GBLVA
HEA
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
J5H
K-O
KOM
L7B
LZ2
M29
M41
MO0
MVM
N4W
N9A
NQ-
O9-
OD.
OHT
OO~
P2P
PC.
PQQKQ
R2-
ROL
RPZ
SAE
SEL
SES
SSZ
TWZ
UBY
UHB
UHU
UNMZH
UV1
WH7
WOW
WUQ
X7M
XH2
XPP
YFH
YOC
YQJ
YYQ
Z5R
ZGI
ZUP
ZXP
AACTN
AAYOK
ADPAM
AFCTW
NCXOZ
PKN
RIG
AAIAV
AGZHU
AHPSJ
ALXNB
ZA5
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7TO
7TS
7U9
H94
K9.
7X8
5PM
ID FETCH-LOGICAL-c692t-ac9a1814788b915ea90c6e31bd24878f58be008cad2845608e7adfe09fcb424a3
ISSN 0002-9343
1555-7162
IngestDate Thu Aug 21 14:34:49 EDT 2025
Fri Jul 11 15:07:54 EDT 2025
Sat Jul 26 02:31:22 EDT 2025
Fri May 30 11:01:23 EDT 2025
Mon Jul 21 09:11:13 EDT 2025
Thu Apr 24 23:10:56 EDT 2025
Tue Jul 01 00:44:10 EDT 2025
Fri Feb 23 02:19:40 EST 2024
Sun Feb 23 10:18:51 EST 2025
Tue Aug 26 17:33:40 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Activated partial thromboplastin time
Epidemiology
Risk factors
Venous thromboembolism
Coagulation
Vascular disease
Medicine
Risk factor
Partial thromboplastin time
Deep vein thrombosis
Cardiovascular disease
Risk
Venous thrombosis
Thromboembolism
Venous disease
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c692t-ac9a1814788b915ea90c6e31bd24878f58be008cad2845608e7adfe09fcb424a3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/2295205
PMID 18328308
PQID 232320161
PQPubID 950
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2295205
proquest_miscellaneous_70374762
proquest_journals_232320161
pubmed_primary_18328308
pascalfrancis_primary_20180776
crossref_primary_10_1016_j_amjmed_2007_10_025
crossref_citationtrail_10_1016_j_amjmed_2007_10_025
elsevier_sciencedirect_doi_10_1016_j_amjmed_2007_10_025
elsevier_clinicalkeyesjournals_1_s2_0_S0002934307010960
elsevier_clinicalkey_doi_10_1016_j_amjmed_2007_10_025
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-03-01
PublicationDateYYYYMMDD 2008-03-01
PublicationDate_xml – month: 03
  year: 2008
  text: 2008-03-01
  day: 01
PublicationDecade 2000
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
– name: New York
PublicationTitle The American journal of medicine
PublicationTitleAlternate Am J Med
PublicationYear 2008
Publisher Elsevier Inc
Elsevier
Elsevier Sequoia S.A
Publisher_xml – name: Elsevier Inc
– name: Elsevier
– name: Elsevier Sequoia S.A
References Tripodi (bib19) 2003; 88
Tsai, Cushman, Rosamond (bib12) 2002; 113
(bib10) 1989; 129
Bank, Libourel, Middeldorp (bib6) 2005; 3
Folsom, Wu, Rosamond (bib13) 1997; 96
Hron, Eichinger, Weltermann (bib4) 2006; 4
Makris, Colvin, Gupta (bib8) 2002; 88
Abdollahi, Cushman, Rosendaal (bib21) 2003; 89
Tripodi, Chantarangkul, Martinelli (bib3) 2004; 104
Fried, Borhani, Enright (bib11) 1991; 1
Begbie, Notley, Tinlin (bib7) 2000; 84
Cushman, Folsom, Wang (bib15) 2003; 101
Chambless, McMahon, Wu (bib14) 1992; 2
White (bib1) 2003; 1
Wilcosky, Chambless (bib16) 1985; 38
Conlan, Folsom, Finch (bib17) 1993; 70
Aboud, Ma (bib2) 2001; 23
Phillips, Smith (bib18) 1991; 44
Svensson, Dahlback (bib5) 1994; 330
Stein, Beemath, Olson (bib20) 2005; 118
Cushman, Tsai, White (bib9) 2004; 117
(10.1016/j.amjmed.2007.10.025_bib10) 1989; 129
Folsom (10.1016/j.amjmed.2007.10.025_bib13) 1997; 96
Wilcosky (10.1016/j.amjmed.2007.10.025_bib16) 1985; 38
Conlan (10.1016/j.amjmed.2007.10.025_bib17) 1993; 70
Tsai (10.1016/j.amjmed.2007.10.025_bib12) 2002; 113
Tripodi (10.1016/j.amjmed.2007.10.025_bib19) 2003; 88
Hron (10.1016/j.amjmed.2007.10.025_bib4) 2006; 4
White (10.1016/j.amjmed.2007.10.025_bib1) 2003; 1
Aboud (10.1016/j.amjmed.2007.10.025_bib2) 2001; 23
Abdollahi (10.1016/j.amjmed.2007.10.025_bib21) 2003; 89
Tripodi (10.1016/j.amjmed.2007.10.025_bib3) 2004; 104
Cushman (10.1016/j.amjmed.2007.10.025_bib9) 2004; 117
Stein (10.1016/j.amjmed.2007.10.025_bib20) 2005; 118
Begbie (10.1016/j.amjmed.2007.10.025_bib7) 2000; 84
Fried (10.1016/j.amjmed.2007.10.025_bib11) 1991; 1
Phillips (10.1016/j.amjmed.2007.10.025_bib18) 1991; 44
Svensson (10.1016/j.amjmed.2007.10.025_bib5) 1994; 330
Makris (10.1016/j.amjmed.2007.10.025_bib8) 2002; 88
Chambless (10.1016/j.amjmed.2007.10.025_bib14) 1992; 2
Bank (10.1016/j.amjmed.2007.10.025_bib6) 2005; 3
Cushman (10.1016/j.amjmed.2007.10.025_bib15) 2003; 101
References_xml – volume: 117
  start-page: 19
  year: 2004
  end-page: 25
  ident: bib9
  article-title: Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology
  publication-title: Am J Med
– volume: 129
  start-page: 687
  year: 1989
  end-page: 702
  ident: bib10
  article-title: The Atherosclerosis Risk in Communities (ARIC) Study
  publication-title: Am J Epidemiol
– volume: 3
  start-page: 79
  year: 2005
  end-page: 84
  ident: bib6
  article-title: Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis
  publication-title: J Thromb Haemost
– volume: 118
  start-page: 978
  year: 2005
  end-page: 980
  ident: bib20
  article-title: Obesity as a risk factor in venous thromboembolism
  publication-title: Am J Med
– volume: 38
  start-page: 849
  year: 1985
  end-page: 856
  ident: bib16
  article-title: A comparison of direct adjustment and regression adjustment of epidemiologic measures
  publication-title: J Chronic Dis
– volume: 89
  start-page: 493
  year: 2003
  end-page: 498
  ident: bib21
  article-title: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use
  publication-title: Thromb Haemost
– volume: 4
  start-page: 752
  year: 2006
  end-page: 756
  ident: bib4
  article-title: Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time
  publication-title: J Thromb Haemost
– volume: 2
  start-page: 723
  year: 1992
  end-page: 733
  ident: bib14
  article-title: Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study
  publication-title: Ann Epidemiol
– volume: 330
  start-page: 517
  year: 1994
  end-page: 522
  ident: bib5
  article-title: Resistance to activated protein C as a basis for venous thrombosis
  publication-title: N Engl J Med
– volume: 113
  start-page: 636
  year: 2002
  end-page: 642
  ident: bib12
  article-title: Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)
  publication-title: Am J Med
– volume: 1
  start-page: 2267
  year: 2003
  end-page: 2270
  ident: bib1
  article-title: The partial thromboplastin time: defining an era in coagulation
  publication-title: J Thromb Haemost
– volume: 44
  start-page: 1223
  year: 1991
  end-page: 1231
  ident: bib18
  article-title: How independent are “independent” effects?
  publication-title: J Clin Epidemiol
– volume: 1
  start-page: 263
  year: 1991
  end-page: 276
  ident: bib11
  article-title: The Cardiovascular Health Study: design and rationale
  publication-title: Ann Epidemiol
– volume: 84
  start-page: 216
  year: 2000
  end-page: 222
  ident: bib7
  article-title: The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP
  publication-title: Thromb Haemost
– volume: 96
  start-page: 1102
  year: 1997
  end-page: 1108
  ident: bib13
  article-title: Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study
  publication-title: Circulation
– volume: 104
  start-page: 3631
  year: 2004
  end-page: 3634
  ident: bib3
  article-title: A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism
  publication-title: Blood
– volume: 88
  start-page: 387
  year: 2002
  end-page: 388
  ident: bib8
  article-title: Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease
  publication-title: Thromb Haemost
– volume: 70
  start-page: 380
  year: 1993
  end-page: 385
  ident: bib17
  article-title: Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis
  publication-title: Thromb Haemost
– volume: 23
  start-page: 411
  year: 2001
  end-page: 416
  ident: bib2
  article-title: Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance
  publication-title: Clin Lab Haematol
– volume: 88
  start-page: 705
  year: 2003
  end-page: 711
  ident: bib19
  article-title: Levels of coagulation factors and venous thromboembolism
  publication-title: Haematologica
– volume: 101
  start-page: 1243
  year: 2003
  end-page: 1248
  ident: bib15
  article-title: Fibrin fragment D-dimer and the risk of future venous thrombosis
  publication-title: Blood
– volume: 330
  start-page: 517
  year: 1994
  ident: 10.1016/j.amjmed.2007.10.025_bib5
  article-title: Resistance to activated protein C as a basis for venous thrombosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199402243300801
– volume: 89
  start-page: 493
  year: 2003
  ident: 10.1016/j.amjmed.2007.10.025_bib21
  article-title: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1613379
– volume: 3
  start-page: 79
  year: 2005
  ident: 10.1016/j.amjmed.2007.10.025_bib6
  article-title: Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2004.01033.x
– volume: 1
  start-page: 263
  year: 1991
  ident: 10.1016/j.amjmed.2007.10.025_bib11
  article-title: The Cardiovascular Health Study: design and rationale
  publication-title: Ann Epidemiol
  doi: 10.1016/1047-2797(91)90005-W
– volume: 2
  start-page: 723
  year: 1992
  ident: 10.1016/j.amjmed.2007.10.025_bib14
  article-title: Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study
  publication-title: Ann Epidemiol
  doi: 10.1016/1047-2797(92)90017-K
– volume: 88
  start-page: 705
  year: 2003
  ident: 10.1016/j.amjmed.2007.10.025_bib19
  article-title: Levels of coagulation factors and venous thromboembolism
  publication-title: Haematologica
– volume: 70
  start-page: 380
  year: 1993
  ident: 10.1016/j.amjmed.2007.10.025_bib17
  article-title: Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis
  publication-title: Thromb Haemost
  doi: 10.1055/s-0038-1649589
– volume: 129
  start-page: 687
  year: 1989
  ident: 10.1016/j.amjmed.2007.10.025_bib10
  article-title: The Atherosclerosis Risk in Communities (ARIC) Study
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a115184
– volume: 23
  start-page: 411
  year: 2001
  ident: 10.1016/j.amjmed.2007.10.025_bib2
  article-title: Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance
  publication-title: Clin Lab Haematol
  doi: 10.1046/j.1365-2257.2001.00421.x
– volume: 84
  start-page: 216
  year: 2000
  ident: 10.1016/j.amjmed.2007.10.025_bib7
  article-title: The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1613999
– volume: 117
  start-page: 19
  year: 2004
  ident: 10.1016/j.amjmed.2007.10.025_bib9
  article-title: Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2004.01.018
– volume: 1
  start-page: 2267
  year: 2003
  ident: 10.1016/j.amjmed.2007.10.025_bib1
  article-title: The partial thromboplastin time: defining an era in coagulation
  publication-title: J Thromb Haemost
  doi: 10.1046/j.1538-7836.2003.00459.x
– volume: 104
  start-page: 3631
  year: 2004
  ident: 10.1016/j.amjmed.2007.10.025_bib3
  article-title: A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism
  publication-title: Blood
  doi: 10.1182/blood-2004-03-1042
– volume: 88
  start-page: 387
  year: 2002
  ident: 10.1016/j.amjmed.2007.10.025_bib8
  article-title: Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1613227
– volume: 101
  start-page: 1243
  year: 2003
  ident: 10.1016/j.amjmed.2007.10.025_bib15
  article-title: Fibrin fragment D-dimer and the risk of future venous thrombosis
  publication-title: Blood
  doi: 10.1182/blood-2002-05-1416
– volume: 96
  start-page: 1102
  year: 1997
  ident: 10.1016/j.amjmed.2007.10.025_bib13
  article-title: Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study
  publication-title: Circulation
  doi: 10.1161/01.CIR.96.4.1102
– volume: 38
  start-page: 849
  year: 1985
  ident: 10.1016/j.amjmed.2007.10.025_bib16
  article-title: A comparison of direct adjustment and regression adjustment of epidemiologic measures
  publication-title: J Chronic Dis
  doi: 10.1016/0021-9681(85)90109-2
– volume: 4
  start-page: 752
  year: 2006
  ident: 10.1016/j.amjmed.2007.10.025_bib4
  article-title: Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2006.01868.x
– volume: 113
  start-page: 636
  year: 2002
  ident: 10.1016/j.amjmed.2007.10.025_bib12
  article-title: Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)
  publication-title: Am J Med
  doi: 10.1016/S0002-9343(02)01345-1
– volume: 44
  start-page: 1223
  year: 1991
  ident: 10.1016/j.amjmed.2007.10.025_bib18
  article-title: How independent are “independent” effects?
  publication-title: J Clin Epidemiol
  doi: 10.1016/0895-4356(91)90155-3
– volume: 118
  start-page: 978
  year: 2005
  ident: 10.1016/j.amjmed.2007.10.025_bib20
  article-title: Obesity as a risk factor in venous thromboembolism
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2005.03.012
SSID ssj0000956
Score 2.1250951
Snippet Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the...
Abstract Background Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant...
Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. In the...
Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 231
SubjectTerms Activated partial thromboplastin time
Biological and medical sciences
Coagulation
Cohort Studies
Epidemiology
Female
General aspects
Humans
Internal Medicine
Male
Medical sciences
Middle Aged
Partial Thromboplastin Time
Public health. Hygiene
Public health. Hygiene-occupational medicine
Risk Factors
United States - epidemiology
Vein & artery diseases
Venous thromboembolism
Venous Thromboembolism - blood
Venous Thromboembolism - epidemiology
Title Activated Partial Thromboplastin Time and Risk of Future Venous Thromboembolism
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0002934307010960
https://www.clinicalkey.es/playcontent/1-s2.0-S0002934307010960
https://dx.doi.org/10.1016/j.amjmed.2007.10.025
https://www.ncbi.nlm.nih.gov/pubmed/18328308
https://www.proquest.com/docview/232320161
https://www.proquest.com/docview/70374762
https://pubmed.ncbi.nlm.nih.gov/PMC2295205
Volume 121
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZbC2Mwxq6d263Tw96Kiy1btvUYRktZuwa6hIW9CFmWSbLciN1B9-t3ZPmaZqTbQ0yQLcv2-XzOJ_lcEPqUhFREIVO2K_3QBv4v7ZgmqS2dNAC6EDueLLx8r4OLof9lREeN_3wRXZLHp_L31riS_5EqtIFcdZTsP0i2Pik0wH-QL2xBwrB9kIx7sihOBpxxpfdqv_HxejmPlyvgxLn2YJzMVceD3KQQOfllMrOWRyv4zapUgtMGPvXXnFZ6ic1v8T_ET1PQWq8mNwuj_fGkKGB0MlB5dnvX0v1lPb5WQL8xgrNsWUCzJ9YAyJvOakTUuGNVCpRSW2elMvZlS1uldYnbgpfX1qHGLNzT7WaZYXoq5lO4V5N9UjvmmcDpbirt6z4_H15d8cHZaPAY7ROYQ4DW3u9d3ny_bAw1K4r71pdXRVYW7n_3R_kbc3m2Ehm8T6kphLJtprLpcNtiMIMX6Hk59cA9g6OX6JFavEJPvpYCfY36NZxwCSfchRPWcMIAJ6zhhJcpNnDCBk54A05v0PD8bPD5wi7rbdgyYCS3hWQCCJ8uqBAzlyrBHBkoz40TAtPaKKVRrEDkUiTAaYApRyoUSaoclsrYJ77w3qK9xXKh3iEsEiZIEBOHJNT3UpelnoCzBj7Qb8ICaiGvepZclsnodU2UGa-8DqfcSEDXSQ11K0jAQnbda2WSsew4nlZi4lWgMZhGDoja0S_c1k9l5euWcZdnhDv8myYUzPO14XT1YkC7Z0lhDTV9wJjHHRzVN0h0ir0wDCx0VAGL19cB8yGP6FmbhT7We8FA6K9-YqFA9jzUGaaA8ljowICweXRgzSPPieCiO_CsD9Cp57t7FpNxkYKeEEaJQw93jnqEnjZq4j3ay9e36gPQ-Dw-Ll_HP-wq91s
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activated+partial+thromboplastin+time+and+risk+of+future+venous+thromboembolism&rft.jtitle=The+American+journal+of+medicine&rft.au=Zakai%2C+Neil+A&rft.au=Ohira%2C+Tetsuya&rft.au=White%2C+Richard&rft.au=Folsom%2C+Aaron+R&rft.date=2008-03-01&rft.issn=1555-7162&rft.eissn=1555-7162&rft.volume=121&rft.issue=3&rft.spage=231&rft_id=info:doi/10.1016%2Fj.amjmed.2007.10.025&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029343%2FS0002934308X00038%2Fcov150h.gif